Tesamorelin TSM2 2mg*10vials

Tesamorelin TSM2 2mg x 10 Vials

Product Overview

Tesamorelin TSM2 is a high-purity modified synthetic growth hormone-releasing hormone analog research peptide, serving as a foundational entry-level product in the TSM series. As a structurally optimized derivative of Sermorelin, Tesamorelin supports molecular stability and targeted lipolysis specificity research compared to traditional GHRH peptides. Through its amino acid modification design, it supports enzymatic degradation resistance research, achieving mild sustained GH and IGF-1 axis activation research, and possesses abdominal and visceral fat metabolism targeting ability research characteristics, distinguishing it from ordinary growth hormone secretagogues. This 2mg low-dose formulation of Tesamorelin is developed for basic research on visceral fat metabolism mechanisms, mild endocrine remodeling, long-term low-dose body composition optimization, and baseline biosafety validation experiments. It serves as a core research material for preclinical studies of lipid metabolism disorders, hepatic lipid accumulation, and age-related metabolic decline.

Core Research Functions

Endogenous GH and IGF-1 Signaling Pathway Activation According to Physiological Rhythms: Supports endogenous GH and IGF-1 signaling pathway stable activation research according to physiological rhythms, gentle orderly pulsed growth hormone secretion triggering studies, and drastic hormone level fluctuations and endocrine feedback inhibition related avoidance research.

Targeted Visceral Fat Degradation and Abdominal Fat Remodeling: Supports targeted visceral fat degradation and abdominal fat remodeling property research, mitochondrial oxidative phosphorylation related gene expression upregulation studies, deep fat metabolism promotion research, hepatic lipid deposition inhibition studies, and mild fatty liver metabolic disorder improvement research.

Basic Physiological Functions Maintenance: Supports lean tissue maintenance, collagen synthesis promotion, and chronic endocrine balance improvement research.

Long-Term Chronic Metabolic Baseline Studies and Low-Dose Lipid Metabolism Mechanism Exploration: Supports long-term chronic metabolic baseline studies, low-dose lipid metabolism mechanism exploration research, and safety threshold validation studies.

Unlike conventional Sermorelin which focuses on overall anabolism, Tesamorelin supports targeted visceral fat degradation and abdominal fat remodeling property research. The 2mg low-dose TSM2 version supports gentle intervention effect research, model tolerability studies, and hormone desensitization related risk research, providing stable reproducible baseline data for targeted lipid regulation and gentle anti-aging endocrine studies.

Core Product Advantages

TSM2 Basic Professional Baseline Version: The entry-level version of the TSM series, based on an optimized molecular structure of traditional GHRH peptides. It retains physiological endocrine activation properties while supporting lipid metabolism targeting specificity enhancement research, providing research capabilities for basic targeted lipolysis research.

Unique Visceral Fat Targeted Regulation: Possesses abdominal and visceral fat remodeling research advantages compared to ordinary GHRH peptides. It specifically supports deep adipose tissue and liver lipid metabolism pathway action research, fat accumulation and abnormal lipid metabolism improvement studies.

Enhanced Molecular Stability and Gentle Sustained Efficacy: Structural modification supports anti-degradation capacity improvement research, achieving longer in vivo retention time and gentler sustained activation effect research compared to unmodified GHRH. It supports hormone spikes related studies and long-term stable metabolic regulation research.

2mg Low-Dose High-Safety Specification: Professional entry-level low-concentration design supports physiological stress avoidance research. This product supports receptor desensitization and metabolic burden related studies caused by high-dose interventions, suitable for long-term chronic experiments and baseline safety studies with controllable risks.

High-Purity Pharmaceutical-Grade Quality: Utilizing aseptic vacuum freeze-drying technology to support peptide activity stable retention research. Each batch undergoes rigorous HPLC purity testing and is accompanied by a complete Certificate of Analysis (COA). The 10-vial aseptic integrated packaging is suitable for routine laboratory basic research, university metabolic mechanism projects, and large-scale wholesale purchases.

Specifications and Quality Control

Format: Lyophilized powder, 2mg per vial. Packaging: 10 vials per pack, dust-free aseptic integrated container. Purity Testing: Full HPLC purity verification with complete Certificate of Analysis (COA).